Abstract:Ferroptosis is a recently recognized form of regulated cell death. It is characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. It can be induced by experimental compounds (e.g., erastin, Ras-selective lethal small molecule 3, and buthionine sulfoximine) or clinical drugs (e.g., sulfasalazine, sorafenib, and artesunate) in cancer cells and certain normal cells (e.g., kidney tubule cells, neurons, fibroblasts, and T cells). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism and can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and desferrioxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin, liproxstatin, and zileuton). Glutathione peroxidase 4, heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 (especially acetylation-defective mutant p53) act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. In this review, we summarize the regulation mechanisms and signaling pathways of ferroptosis and discuss the role of ferroptosis in disease.

Ferroptosis and microbial pathogenesis

Insight into the Role of Ferroptosis in Non-neoplastic Neurological Diseases

A novel mitochondrial regulon for Ferroptosis during fungal pathogenesis

Ferroptosis-Like Death in Microorganisms: A Novel Programmed Cell Death Following Lipid Peroxidation

When ferroptosis meets pathogenic infections

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease

Ferroptosis: Regulatory mechanisms and potential targets for bone metabolism: A review

Ferroptosis-molecular mechanisms and newer insights into some diseases

Ferroptosis: Iron-mediated cell death linked to disease pathogenesis

Ferroptosis: molecular mechanisms and health implications

Ferroptosis: past, present and future

Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy

Ferroptosis: principles and significance in health and disease

Ferroptosis in life: To be or not to be

Ferroptosis as a novel form of regulated cell death: Implications in the pathogenesis, oncometabolism and treatment of human cancer

Ferroptosis: mechanisms, biology and role in disease

Ferroptosis, a new form of cell death, and its relationships with tumourous diseases

Iron Metabolism in Ferroptosis

Ferroptosis in viral infection: the unexplored possibility

Ferroptosis: A double-edged sword

Ferroptosis: process and function